Cited by Construction of M2 macrophage-related gene signature for predicting prognosis and revealing different immunotherapy response in bladder cancer patients

Organ-specific tumor response to enfortumab vedotin in metastatic urothelial carcinoma: a multicenter retrospective study DOI

Fumihiko Urabe,

Y Taneda,

Naoki Uchida

et al.

Japanese Journal of Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: April 8, 2025

Abstract Background Despite advancements in treatment options for metastatic urothelial carcinoma (mUC), therapeutic choices remain limited patients with disease refractory to platinum-based chemotherapy (PBC) and immune checkpoint inhibitors (ICIs). Enfortumab vedotin (EV) has demonstrated significant efficacy later lines of therapy mUC; however, its organ-specific responses uncertain. Methods We conducted a retrospective study 69 mUC who received EV following PBC ICIs. Efficacy was assessed using Response Evaluation Criteria Solid Tumors, response rates (OSRR) control (OSCR) calculated across different sites. Multivariate Cox regression analysis performed identify independent predictors progression survival. Results The median progression-free survival (PFS) 8.3 months, whereas the overall (OS) 18.0 months. objective rate (ORR) 53.6%, (DCR) 82.6%. OSCR ≥70% all sites, confirming broad EV. Liver metastases exhibited highest OSRR at 66.7%, bone had lowest 12.5%. Tumor burden reduction significantly lower compared other Disease predominantly observed target lesions, time 3 Eastern Cooperative Oncology Group performance status serum C-reactive protein levels were identified as PFS OS. Conclusion favorable tumor mUC, particularly high against liver metastasis. However, metastases. No differences observed.

Language: Английский

Citations

The Role of Proteomics and Genomics in the Development of Colorectal Cancer Diagnostic Tools and Potential New Treatments DOI

Gaurav Paraskar,

Sankha Bhattacharya,

Kuttiappan Anitha

et al.

ACS Pharmacology & Translational Science, Journal Year: 2025, Volume and Issue: unknown

Published: April 10, 2025

The complex molecular mechanisms involving genetic and epigenetic modifications contribute to colorectal cancer (CRC), which remains a significant threat world health. This review elucidates the role of proteomics genomics in progression, diagnosis, treatment cancers. All potential key pathways involved CRC, including WNT, MAPK, PI3K, TGF-β pathways, are reviewed with systematic analysis, concluding their involvement tumorigenesis therapeutic resistance. Emerging next-generation sequencing technologies revealed critical mutations that relevant CRC development. Proteomics has contributed identifying biomarkers post-translational hold promise for targeted therapies. Recent technological advances have provided functional insights into protein signaling networks through mass spectrometry integrated proteogenomic approaches. work emphasizes biomarker-driven translational efforts integrate genomic expression profiles refine personalized treatments. application innovations liquid biopsy computational biology advocates precision medicine paths improve outcomes CRC. Now, pharmacoproteomics offers novel domains drug discovery resistance management serves as foundation comprehensive paradigms.

Language: Английский

Citations

RAP1GAP is a prognostic biomarker and correlates with immune infiltrates in bladder cancer DOI